163 related articles for article (PubMed ID: 25831053)
1. Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer.
Heijmen L; ter Voert EE; Oyen WJ; Punt CJ; van Spronsen DJ; Heerschap A; de Geus-Oei LF; van Laarhoven HW
PLoS One; 2015; 10(4):e0120823. PubMed ID: 25831053
[TBL] [Abstract][Full Text] [Related]
2. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET.
Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C
J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
[TBL] [Abstract][Full Text] [Related]
5. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
6. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
[TBL] [Abstract][Full Text] [Related]
7. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
[TBL] [Abstract][Full Text] [Related]
8. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
9. Correlation between apparent diffusion coefficients on diffusion-weighted MRI and standardized uptake value on FDG-PET/CT in pancreatic adenocarcinoma.
Sakane M; Tatsumi M; Kim T; Hori M; Onishi H; Nakamoto A; Eguchi H; Nagano H; Wakasa K; Hatazawa J; Tomiyama N
Acta Radiol; 2015 Sep; 56(9):1034-41. PubMed ID: 25267921
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to Y90-radioembolization.
Barabasch A; Kraemer NA; Ciritsis A; Hansen NL; Lierfeld M; Heinzel A; Trautwein C; Neumann U; Kuhl CK
Invest Radiol; 2015 Jun; 50(6):409-15. PubMed ID: 25763526
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.
Correa-Gallego C; Gavane S; Grewal R; Cercek A; Klimstra DS; Gewirtz AN; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N; D'Angelica MI
HPB (Oxford); 2015 Jul; 17(7):644-50. PubMed ID: 26010778
[TBL] [Abstract][Full Text] [Related]
12. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
[TBL] [Abstract][Full Text] [Related]
13. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer.
Soydal C; Kucuk ON; Gecim EI; Bilgic S; Elhan AH
Nucl Med Commun; 2013 May; 34(5):501-6. PubMed ID: 23478586
[TBL] [Abstract][Full Text] [Related]
15. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
[TBL] [Abstract][Full Text] [Related]
16. Predicting Treatment Response of Colorectal Cancer Liver Metastases to Conventional Lipiodol-Based Transarterial Chemoembolization Using Diffusion-Weighted MR Imaging: Value of Pretreatment Apparent Diffusion Coefficients (ADC) and ADC Changes Under Therapy.
Lahrsow M; Albrecht MH; Bickford MW; Vogl TJ
Cardiovasc Intervent Radiol; 2017 Jun; 40(6):852-859. PubMed ID: 28357571
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging.
Baba S; Isoda T; Maruoka Y; Kitamura Y; Sasaki M; Yoshida T; Honda H
J Nucl Med; 2014 May; 55(5):736-42. PubMed ID: 24665089
[TBL] [Abstract][Full Text] [Related]
18. The role of routine clinical pretreatment 18F-FDG PET/CT in predicting outcome of colorectal liver metastasis.
Tam HH; Cook GJ; Chau I; Drake B; Zerizer I; Du Y; Cunningham D; Koh DM; Chua SS
Clin Nucl Med; 2015 May; 40(5):e259-64. PubMed ID: 25742225
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Total Lesion Glycolysis Measured by 18F-FDG-PET/CT in Patients with Colorectal Cancer.
Ogawa S; Itabashi M; Kondo C; Momose M; Sakai S; Kameoka S
Anticancer Res; 2015 Jun; 35(6):3495-500. PubMed ID: 26026116
[TBL] [Abstract][Full Text] [Related]
20. Variability of target and normal structure delineation using multimodality imaging for radiation therapy of pancreatic cancer.
Dalah E; Moraru I; Paulson E; Erickson B; Li XA
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):633-40. PubMed ID: 24755533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
